Home     About Us     Medic-All     Bio B2B     Hot Topic     Expo     Login | Join Now     Search Button
Exhibitor List
Keyword Search

A Plus Biotechnology Corporation Limited

Presently, For different grade of knee osteoarthritis (OA), the knee can be treated with arthroscopy, high tibial osteotomy (HTO), semi- or total knee replacement (TKR). As OA patients are getting younger, and TKR is an unrecoverable surgical procedure, the only choice is a second-revision surgery once the knee is infected or worn. The revision TKR will increase the difficulty of the surgery and sequelae. Therefore, for young patients with early and medium degenerative or traumatic osteoarthritis, HTO is a good choice among the treatments.

HTO realigns the weight bearing line (WBL) of lower limb by cutting from the medial or lateral proximal tibial and extracting or closing the wedge. The use of locking plate can provide stable fixation during weight bearing or knee motion. In the past, surgical failure were mainly caused by the fracture or loosening of plate/screw, leading to wedge collapse and lose of correction, which then decrease surgeons’ confidence. Thus, the stability that the plate can provide is one of the key factors for successful surgery. This project designed a 3d-printed patient-specific instrument (PSI) guide in the vision of improving the above mentioned failure modes, with minimally invasive and anatomical fit, to achieve safe, fast and accurate Osteotomy. The goal is to increase the successful rate of osteotomy. The advantages are: 1) Anatomical bone plate can have similar profile with the patient’s bone surface, 2) Extend the posterior covering area of the bone plate for distributing the stresses, 3) Enhace the mechanical strength and supporting capability to improve postoperative stability, 4) Locking screws are used to avoid loosening of the screws. In addition, 5) Reduce the operation time, 6) Lower the radiation exposure, and 7) Decrease the risk of intraoperative fracture can be achieved through the precision cut by the assistance of PSI.


BRAXX focuses on developing novel radiation treatment solution for cancers. BRAXX designs new generation of brachytherapy applicator for esophageal cancer according to clinical needs; this applicator gives clinicians and radiologists a better tool deliver therapy.

Cooperation projects and needs
1.Clinical Corporation
2.Sales Partner

China Medical College

Myopia (also known as nearsightedness) is a common eye disease but it is also a major cause of blindness. Asians have the highest risk for myopia with a prevalence of 85%. Severe myopia (worse than -6 diopter) will abnormally elongate the eyeball axial length, which causes pathological change of eyeball leading to increases of severe complications diseases including macular damage, retinal detachment, glaucoma, premature cataract or even blindness.

So far, two ways have been used to “correct” myopia: eyedrop treatment and glasses (including lasik surgery). Unfortunately, there is ONE effective eyedrop, Atropine, to treat myopia. Atropine can prevent/reduce eyeball elongation leading to treat myopia and to prevent myopia-induced eye diseases. However, Atropine can dilate pupils which not only causes photo-phobia, but also leads to the photo-damage to the eyes. Due to the side effects, patients and even eye doctors often reject Atropine. Although myopia can be simply corrected by glasses or lasik surgery, these methods do not prevent myopia progression or myopia-induced complications. Accordingly, there is unmet medical need for myopia, which is particularly important for the Asian populations.

We have identified that overexpression of microRNA-328 is a risk factor for myopia. We designed several microRNA-328 inhibitors and filed patents for myopia treatment. Using the inhibitor via eye drop, we successfully treated myopic mice and rabbits and recovered their eyeball to the normal ranges. No side effect or toxicity was found based on the toxicity studies. We expect to file IND in 2019 and move our product to human clinical trials.
Cooperation projects and needs
1. We expect to out-licensing our Products/Technology
2. We are looking for investors

Chung Yuan Christian University

Redox Medicare is established by a group of energetic and creative young scientists from Department of Bioscience Technology and Biomedical Engineering, Chung Yuan Christian University. In the early summer of 2017, the American Board of toxicologist, Professor William Ming-Wei Chao, and his research team, established “Redox Medicare” in the hope of developing health care products and dietary supplements that could assist the human body perform effective internal cleansing and fight against the harm caused by toxic substances, based on what they had learned throughout their lives. Our idea is quite simple: detoxification (Just Redox), nothing else.



Everfront Biotech Inc.

New drug discovery and clinical trail.

Forlab Clinic

With the advent of biomedical science, new biotechnology not only allows us to acquire the genetic codes, and also steers the current medical practice into precision medicine. However, the communication between biotech providers and clients becomes more difficult than ever in this situation. Counseling has, therefore, become a must for precision medicine. In this context, Forlab Clinic intends to be the bridge of precision medicine, and will provides the services as follows:
* For patients looking for help of high technology, Forlab Clinic provide pre-testing counseling.
* For patients received testing of precision medicine, Forlab Clinic provide post-testing counseling.
* For those who are care about their status of health, Forlab Clinic provides whole exome sequencing (WES) with detailed interpretation.

Our mission is to be the bridge of precision medicine; and vision the leader of the pack.

Guzip Biomarkers Corporation

Development of DNA methylation biomarkers for endometrial cancer detection
Guzip Biomarkers Corp. has put great effort into developing novel epigenetic biomarkers to help in the diagnosis of endometrial cancer. We have analyzed about 350 samples of endometrial cancer patients, filtered out several specific genes, and proved that these genes are associated with the risk for developing endometrial cancer. These biomarkers can show whether the patient suffers from endometrial cancer from Pap smear specimens or related samples. It has the advantages of high specificity and sensitivity, which makes it possible to become a mainstream IVD product.
Cooperation projects and needs
Investors seeking
Strategic alliance

Institute of Nuclear Energy Research

Institute of Nuclear Energy Research has successfully developed “Dolacga” Liver Reserve Imaging Agent. We have got the approval of USFDA phase 1 clinical trial on Jan 20, 2018. INER “Dolacga” Liver Reserve Imaging Agent is Taiwan Brand innovative new drug. By specific binding with liver receptor, it can be applied as indicator of liver reserve measurement for hepatectomy, liver transplantation, or chronic liver disease therapeutic evaluation. The innovation has more than 19 patents from USA, Japan, Europe and Taiwan. In addition, It owns the 10th National Innovation Award, award, the 66th Nuremberg Invention Award, and 2015 Taipei International Invention Platinum Award, which is the biggest prize of Taipei International Invention Show and Technomart. We will have a first-in-human peptide-type Liver Reserve Imaging in the world soon.

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan

“The technology with diverse applications for depolymerizing and saccharifying lignocellulosic biomass” can depolymerize and saccharify lignocellulosic biomass, thus convert agro-forestry residues and fast-growth energy crops into valued industrial raw materials. The depolymerization system has special and innovative design for the heating and the continuous input and output, also special design of the mixing blades. It can continuously transport cellulosic materials; completely mix them with catalyst, fast heat up to reaction temperature, and instantly flash and discharge. It has been validated using several feedstocks to be in compliance with the requirements for commercial application as long-term stability, high efficiency, low energy consumption, and low maintenance cost. It can depolymerize cellulosic materials into xylose (or xylooligomer), cellulose, and lignin. If combined with the low-cost saccharification process of this technology and via bio-fermentation process, the cellulosic sugars can then be converted into industrial building blocks, such as: ethanol or lactic acid. The “eco-friendly specialty strain FRIEND for lignocellulosic ethanol production” can rapidly convert both glucose and xylose derived from lignocellulosic materials into ethanol. The high performance and robustness capabilities of FRIEND have been validated to achieve an overall production yield enhancement of 10-35%. This technology can be applied to low-carbon energy (bio-green power, bio-gas and bio-fuels), high-end medical materials (medical grade PLA), high-valued industrial materials (nano-fiber, carbon fiber), food and animal feed (xylose, xylooligomer, xylitol) industries. Its market is extensive and highly potential.
Cooperation projects and needs
We are seeking developers for technology licensing.